Artivion: The $100,000 Speed Bump That Won't Go Away

A PMA that was supposed to unlock the AMDS launch hasn't, EBITDA is shrinking, and the real catalyst — Nexus — is still two months and one leadership transition away

AORT · Earnings Call · 2026-11-05

The Growth Story With a Profit Problem

On the surface Artivion's fiscal third quarter reads like a growth story: $123.8 million of revenue, up 9% in constant currency, with three of four product lines growing. Underneath, the profit engine is sputtering. Adjusted EBITDA fell 8% to $22.5 million and the margin shed about 350 basis points, landing at 18.2%. The culprit is early-stage manufacturing costs at the Onyx and Nexus plants plus an unfavorable mix — gross margin slid to 61.4% from 65.6% a year ago. Management insists this is all timing: the plants will eventually carry far higher volume and drive unit costs down. Perhaps. But the market has already voted — the stock trades around $26, roughly 47% below its November 2025 peak of $47.63, and the last 90 days show only a modest 7.6% bounce off the lows. The real story, though, isn't margin. It's the recurring arithmetic of one launch.

The $100,000 Speed Bump

AMDS, Artivion's aortic dissection device, requires a hospital to buy a "starter set" — four devices upfront for roughly $100,000. This quarter's highest-momentum keyword was set sale, a theme that has been climbing for quarters: starter set topped the Q2 list. CEO Pat Mackin's framing is unchanged from the last several calls:

Meanwhile, U.S. AMBF set sales remain challenged. We view this dynamic as administrative and transient.
Pat Mackin, Chairman, President · 2026-11-05

Transient is doing a lot of work in that sentence. In Q1 (May), management argued the pending PMA would help break the logjam: “We do think that the PMA will help... We are also working to knock down some of the barriers” — Pat Mackin, CEO · 2026-05-07, and CFO Lance Berry was explicit — “We think we will see a reacceleration of starter set sales.” — Lance Berry, COO and CFO · 2026-05-07 By the Q2 call in August, the CEO was “very bullish on the second half, what we can do with AMDS.” — James Mackin, Chief Executive Officer · 2026-08-06 Now the PMA is in hand, and the bottleneck has simply moved. Value Analysis Committees, it turns out, were never the obstacle. The obstacle is the purchase order: “we thought getting through the VACs, and we're not having any problems getting through the VACs. In fact, I don't think there's any VAC that we've not gotten through. The new piece is getting the PO actually in the $100,000.” — Pat Mackin, Chairman, President · 2026-11-05 The keyword cluster tells the same story — VAC approval and Value Analysis are recurring anchors, but the friction has migrated to hospital bureaucracy. What genuinely is improving is utilization: implant increases rose sequentially, and a new reimbursement code, DRG 209, now pays hospitals richly for complex arch work — except that “it's amazing to me that hospitals more and more, like just hospitals aren't aware of the information.” — Pat Mackin, Chairman, President · 2026-11-05 A reimbursement tailwind nobody has told the customers about is not yet a tailwind.

Nexus: The Anti-AMDS Launch

The bull case pivots to Nexus, the aortic-arch device acquired alongside the EndoSpan business, launching January 1, 2027. The pitch is that it sidesteps the AMDS trap entirely: elective cases, no consignment, no upfront purchase. As Mackin puts it, “there is no consignment, but there is no inventory. They don't have to buy anything upfront. They basically bring the devices in for the procedure with our rep. They do the case, and then we get the PO.” — Pat Mackin, Chairman, President · 2026-11-05 The Commercial launch machinery is being assembled now — surgeon training in December, a launch meeting at VEITH in two weeks. But 2026 gets essentially no Nexus revenue, and management flags a combined EBITDA-neutral 2027. The fourth leg, the ARTISAN trial, has 56 patients enrolled with the first 30 presented at a November 19 late-breaker — a 2029 approval and $80 million opportunity.

The Math Nobody Wants to Talk About

Two things sit awkwardly beneath the guidance. First, the implied Q4 growth rate is only mid-single-digit, which Berry attributes to FX flipping from tailwind to headwind and to the preservation-services line giving back an overachievement: “a lot of the overachievement in Q3 is just going to reverse in Q4 on that preservation services line.” — Lance Berry, Executive Vice President, Chief Operating Officer · 2026-11-05 That's the second consecutive quarter this timing reversal has been teed up. Second, the Perclot wind-down creates a 2027 cliff — “a 2 percentage point revenue growth headwind and a 4 percentage point EBITDA growth headwind attributable to the completion of our per-clot agreement with Baxter.” — Lance Berry, Executive Vice President, Chief Operating Officer · 2026-11-05 The balance sheet tightens the story. Free cash flow swung to negative $17.6 million from positive $17.7 million a year ago — free cash flow — and effective net cash sits near negative $293 million on the latest filing, with net leverage at 3.5x. Berry's deleveraging plan is blunt: “realistically, the leverage reduction is going to come primarily through EBITDA growth.” — Lance Berry, Executive Vice President, Chief Operating Officer · 2026-11-05 That is a circular dependency when EBITDA is falling and the next big product doesn't contribute until 2027. Artivion is stacking a genuinely attractive set of four U.S. aortic platforms worth roughly $430 million in addressable opportunity. But this quarter's report is a reminder that a differentiated device portfolio is not the same as a commercial flywheel. The company keeps telling investors the starter-set problem is transient. Three quarters in, the honest read is that the hospital procurement system is the binding constraint, and the market has repriced the stock accordingly — a price-to-revenue multiple of about 2.3x, near the low end of its decade-long range. Until the implants convert into reorders without the $100,000 toll, the narrative stays on the shelf.